Status and issues of preclinical evaluation of the therapeutic effects of newly developed antifungal agents

Japanese Journal of Medical Mycology

Volumn 45, Issue 2, 2004, Pages 83-91

  Uchida, Katsuhisa ^a   Yamaguchi, Hideyo ^a  

^a TEIKYO UNIVERSITY   (Japan)

Author keywords

Antifungal activity; Antifungal agents; Evaluation of the therapeutic effects; Preclinical evaluation

Indexed keywords

ALAMAR BLUE; AMPHOTERICIN B; ANTIFUNGAL AGENT; CHLORMETHINE; CORTISONE ACETATE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DYE; FLUCONAZOLE; FLUCYTOSINE; FLUOROURACIL; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MICONAZOLE; NEW DRUG; POSACONAZOLE; PREDNISOLONE; RAVUCONAZOLE; TERBINAFINE; TETRACYCLINE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; CLINICAL LABORATORY; COLONY FORMING UNIT; DOSE RESPONSE; DRUG EFFICACY; DRUG SCREENING; DRUG SENSITIVITY; IN VITRO STUDY; IN VIVO STUDY; INFECTION; JAPAN; MEDICAL SOCIETY; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; PATHOPHYSIOLOGY; PRECLINICAL EVALUATION; REPRODUCIBILITY; REVIEW; STANDARDIZATION; TREATMENT OUTCOME; UNITED STATES;

ANIMALIA;

EID: 2442716200     PISSN: 09164804     EISSN: None     Source Type: Journal    
DOI: 10.3314/jjmm.45.83     Document Type: Review

References (52)

1. National Committee for Clinical Laboratory Standards: Antifungal Susceptibility Testing. Committee Report, NCCLS Document M20-CR, NCCLS vol.5, no.17, 1985.
2. Pfaller MA, Burmeister L, Bartlett MS, Rinaldi MG: Multicenter evaluation of four methods of yeast ionculum preparation. J Clin Microbiol 26: 1437-1441, 1988.
3. Pfaller MA, Rinaldi MG, Galgiani JN, Bartlett MS, Body BA, Espinel-Ingroff A, Fromtling RA, Hall GS, Hughes CE, Odds FC, Sugar AM: Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother 34: 1648-1654, 1990.
4. Espinel-Ingroff A, Kish CW, Kerkering TM, Fromtling RA, Bartizalk K, Galgiani JN, Villareal K, Pfaller MA, Gerarden T, Rinaldi MG, Fothergill A: Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol 30: 3138-3145, 1992.
5. Fromtling RA, Galgiani JN, Pfaller MA, Espinel-Ingroff A, Bartizal KF, Bartlett MS, Body BSA, Frey C, Roberts GD, Nolte FB, Odds FC, Rinaldi MG, Sugar AM, Villareal K: Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts. Antimicrob Agents Chemother 37: 39-45, 1993.
6. National Committee for Clinical Laboratory Standards: Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Proposed Standard. NCCLS Document M27-P, NCCLS vol.12, no.25, 1992.
7. National Committee for Clinical Laboratory Standards: Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Tentative Standard. NCCLS Document M27-T, NCCLS vol.15, no.10, 1995.
8. National Committee for Clinical Laboratory Standards: Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard. NCCLS Document M27-A, NCCLS vol.17, no.9, 1997.
9. National Committee for Clinical Laboratory Standards: Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard-Second Edition. NCCLS Document M27-A2, NCCLS vol.22, no.15, 2002.
10. Chryssanthou E, Cuenca-Estrella: Comparison of the antifungal susceptibility testing Subcommittee of the European Antibiotic Susceptibility Testing Proposed Standards and E-test with the NCCLS broth microdilution method for variconazole and caspofungin susceptibility testing of yeast species. J Clin Microbiol 40: 3841-3844, 2002.
11. Galgiani JN: Antifungal susceptibility tests. Antimicrob Agents Chemother 31: 1867-1870, 1987.
12. Espinel-Ingroff A, Dawson K, Pfaller M, Anaissie E, Breslin B, Dixon D, Fothergill A, Paetznick V, Peter J, Rinaldi M, Walsh T: Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother 39: 314-319, 1995.
13. National Committee for Clinical Laboratory Standards: Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium-Forming filamentous Fungi; Proposed Standard. NCCLS Document M38-P, NCCLS vol.18, no.13, 1998.
14. National Committee for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standards. NCCLS Document M38-A, NCCLS vol.22, no.16, 2002.
15. Yoshida T, Uchida K, Yamaguchi H: An ATP bioluminescence assay applicable to rapid fluconazole susceptibility testing of dermatophytes. Microbiol Immunol 41: 377-386, 1997.
16. Yamaguchi H, Uchida K, Nagino K, Matsunaga T: Usefulness of a colorimetric method for testing antifungal drug susceptibilities of Aspergillus species to voriconazole. J Infect Chemother 8: 374-377, 2002.
17. Uchida K, Yokota N, Yamaguchi H: In vitro antifungal activity of posaconazole against various pathogenic fungi. Int J Antimicrob Agents 18: 167-172, 2001.
18. Uchida K, Nishiyama Y, Yokota N, Yamaguchi H: In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. J Antibiotics 53: 1175-1181, 2000.
19. Uchida K, Nishiyama Y, Tanaka T, Yamaguchi H: In vitro activity of novel imidazole agent NND-502 against Malassezia species. Int J Antimicrob Agents 21: 234-238, 2003.
20. Garau M, Pereiro M, del Palacio A: In vitro susceptibilities of Malassezia species to a new azole, albaconazole (UR-9825), and other antifungal compounds. Antimicrob Agents Chemother 47: 2342-2344, 2003.
21. Gonzalez GM, Sutton DA, Thompson E, Tijerina R, Rinaldi MG: In vitro activities of approved and investigational antifungal agents against 44 clinical isolates of basidiomycetous fungi. Antimicrob Agents Chemother 45: 633-635, 2001.
22. Nakai T, Uno J, Ikeda F, Tawara S, Nishimura K, Miyaji M: In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: Comparison of yeast-like and mycelial forms. Antimicrob Agents Chemother 47: 1376-1381, 2003.
23. Ramage G, Vande Walle K, Wickes BL, Lopez-Ribot JL: Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 45: 2475-2479, 2001.
24. Ramani R, Chaturvedi V: Flow cytometry antifungal susceptibility testing of pathogenic yeasts other than Candida albicans and comparison with the NCCLS broth microdilution test. Antimirob Agents Chemother 44: 2752-2758, 2000.
25. Louie A, Liu W, Miller DA, Sucke AC, Liu Q, Drusano GL, Mayers M, Miller MH: Effecacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans. Atimicrob Agents Chemother 43: 2831-2840, 1999.
26. Kamai Y, Harasaki T, Ohya S, Uchida K, Yamaguchi H: R-120758, a novel triazole antifungal agent: In vivo antifungal activity. 40th ICAAC Abstract p.201, Toronto, Ontario, Canada, Sept 17-20, 2000.
27. Yamamoto K, Makimura K, Sudo T, Shibuya K, Uchida K, Yamaguchi H: Experimental disseminated trichosporonosis in mice: tissue distribution and therapy with antifungal agents. J Med Vet Mycol 35: 411-418, 1997.
28. Gonzalez GM, Tijerina R, Najvar LK, Bocanegra R, Rinaldi MG, Loebenberg D, Graybill JR: Acrivity of posaconazole against Pseudallescheri boydii: In vitro and in vivo assays. Antimicrob Agents Chemother 47: 1436-1438, 2003
29. Guarro J, Pujol I, Mayayo E: In vitro and in vivo experimental activities of antifungal agents against Fusarium solani. Antimicrob Agents Chemother 43: 1256-1257, 1999.
30. Connolly P, Wheat LJ, Schnizlein-Bick C, Durkin M, Kohler S, Smedema M, Goldberg J, Brizendine E, Loebenberg D: Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary change in immunocompromised mice. Antimicro Agents Chemother 44: 2604-2608, 2000.
31. Sugar AM, Liu X-P: Combination antifungal therapy in treatment of murine pulmonary mucormycosis: Roles of Quinolona and azoles. Antimicrob Agents Chemother 44: 2004-2006, 2000.
32. Martinez A, Aviles P, Jimenez E, Caballero J, Gargallo-Viola D: Activities of sordarines in experimental models of candidiasis, aspergillosis, and pneumocystosis. Antimicrob Agents Chemother 44: 3389-3394, 2000.
33. Fujita S: Experimental tinea pedis induced by nonabrasive unoculation of Trichophyton mentagrophytes arthrospores on the planter part of a guinea pig foot. J Med Vet Mycol 25: 202-213, 1987.
34. Uchida K, Yamaguchi H: Assessment of in vivo activity of bifonazole against dermatophytic infection in guinea pig on the basis of the amount of a specific fungal cell wall component chitin in the infected skin. Dermatol 169: 47-50, 1984.
35. Jap J Antibiot 47: 1407-1412, 1994.
36. Jpn J Antibiot 47: 1401-1406, 1994.
37. Uchida K, Yamaguchi H, Sibiya K: Production of an experimental model of tinea unguium in guinea pig. 12th Congress of the International Society for human and animal Mycology, Adelaide, 1994.
38. Uchida K, Tanaka T, Yamaguchi H: Achievement of complete mycological cure by topical antifungal agent NND-502 in guinea pig model of tinea pedis. Microbiol Immunol 47: 143-146, 2003.
39. Maebashi K, Itoyama T, Uchida K, Yamaguchi H: A novel model of cutaneous candidiasis produced in prednisolon-treated guinea-pigs. J Med Vet Mycol 32: 349-359, 1994.
40. Jpn J Antibiot 46: 896-903, 1993.
41. Niwano Y, Seo A, Kanai K, Hamaguchi H, Uchida K, Yamaguchi H: Therapeutic efficacy of lanoconazole, a new imidazole antimycotic agents, for experimental cutaneous candidiasis in guinea pigs. Antimicrob Agents Chemother 38: 2204-2206, 1994
42. Aviles P, Falcoz C, San Roman R, Garallo-Viola D: Pharmacokinetics-pharmcodynamics of a sordarin dervative (GM 237354) in a murine model of lethal candidiasis. Antimicrob Agents Chemother 44: 2333-2340, 2000.
43. Groll AH, Mickiene D, Petraitiene R, Petratis V, Lyman CA, Bacher JS, Piscitell SC, Walsh TJ: Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): Reappraisal of its efficacy in neutropenic animal models of opportiunistic mycoses of using optimal plasma sampling. Antimicrob Agents Chemother 45: 2845-2855, 2001.